Talk:Agency for Health Technology Assessment and Tariff System

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Further sources[edit]

In case of questions re. notability, the Agency's decision making process has been a subject of many academic studies:

  • Wilk, N.; Wierzbicka, N.; Skrzekowska-Baran, I.; Tomassy, J.; Kloc, K.; Stankowicz, P.; Włodek, A. (2016). "Real World Evidence in Decision-Making Processes on Public Funding of Drugs in Poland". Value in Health. 19 (7): A449. doi:10.1016/j.jval.2016.09.595.
  • Wilk, N.; Wierzbicka, N.; Skrzekowska-Baran, I.; Moćko, P.; Tomassy, J.; Kloc, K. (2017). "Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes". Public Health. 145: 51–58. doi:10.1016/j.puhe.2016.12.025. PMID 28359391.
  • Kleijnen, S.; Lipska, I.; Leonardo Alves, T.; Meijboom, K.; Elsada, A.; Vervölgyi, V.; d'Andon, A.; Timoney, A.; Leufkens, H. G.; De Boer, A.; Goettsch, W. G. (2016). "Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries". Annals of Oncology. 27 (9): 1768–1775. doi:10.1093/annonc/mdw233. PMID 27329251.
  • Wranik, Wiesława Dominika; Zielińska, Dorota Anna; Gambold, Liesl; Sevgur, Serperi (2019). "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland". Health Policy. 123 (2): 191–202. doi:10.1016/j.healthpol.2018.12.001. PMID 30554792.

- and many many others. To me, this proves that the subject is fairly notable, even in the niche field of health technology assessment. — kashmīrī TALK 18:19, 1 March 2019 (UTC)[reply]